Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

First-line Disitamab Vedotin/Toripalimab Ups Survival in HER2+ mUC

Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.

HER3 Reclaims Spotlight as a Crucial Target in Cancer Therapy Advances

In the complex landscape of oncology, the ErbB family of receptor tyrosine kinases has long captivated researchers with its pivotal role in cell growth and tumor progression. Among these, HER3—or human epidermal growth factor receptor 3—has historically been something of an enigma. Once dismissed as a subordinate member due to its impaired kinase activity, recent advancements have repositioned HER3 at the forefront of cancer biology. Emerging ev…

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

The phase 3 RC48-C016 trial met its primary end points.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.